<DOC>
	<DOC>NCT00255463</DOC>
	<brief_summary>The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.</brief_summary>
	<brief_title>Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Measurable (stage IIIIB) non meta static non inflammatory breast cancer Patients must post menopausal women who in the opinion of investigator would be likely to benefit from endocrine therapy. Postmenopausal patients are defined as: Natural menopause with last menses &gt; 1 year ago, Radiation induced oophorectomy with last menses &gt; 1 year ago, Serum FSH and LH levels clearly in the postmenopausal range for the institution. Bilateral oophorectomy Other current or previous (to last 5 years) malignancies, other metastases, abnormal blood chemistry, lung/ heart/kidney/liver abnormalities, Hormonal treatment within the last 2 weeks, previous hormonal treatment for invasive cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>